



EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

ASX Release

APPENDIX 4C – 31 DECEMBER 2018 QUARTERLY CASHFLOW REPORT

Highlights:

- *Successful ASX listing after oversubscribed \$6,000,000 Initial Public Offering*
- *Positive safety observations from healthy human trials*
- *Further clinical prototype device advancement*
- *EMvision Received ISO 13485 Certification from TÜV Rheinland*
- *Initiated the collection of liver samples to inform adjacent NAFLD / NASH Torso Scanner opportunity*

EMvision Medical Devices Limited (ASX: EMV) (“EMvision” or the “Company”) is pleased to lodge the attached Appendix 4C Quarterly Cashflow Report for the 6 month period ended 31 December 2018.

During the quarter, EMvision commenced trading on Australian Securities Exchange (“ASX”) following the successful completion of its oversubscribed initial public offering. The Company raised AUD \$6,000,000 via the issue of 24,000,000 shares at \$0.25 each, with strong support from institutional investors, clinicians and family offices.

In partnership with The University of Queensland, EMvision is developing and commercialising medical imaging diagnostics for various disease states and medical emergencies. The Company’s initial focus is a portable, cost effective, non-invasive brain scanner to monitor and help diagnosis of brain injuries and stroke by creating rapid 3D images of the brain. Key activities undertaken during the quarter are outlined below.

Positive safety observations from healthy human trials

EMvision commenced healthy human trials to evaluate how the clinical prototype brain scanner and system would perform in a real-world environment. The purpose of these trials is to test a clinical prototype on healthy human volunteers to provide key learnings and the necessary safety and usability information. This information is required for the Company’s ethics requirements for the Company’s planned clinical trial.

Results from these trials were announced to the ASX on 24th January 2019 in an announcement titled “Positive Safety Observations From Healthy Human Trials for Brain Scanner Program”.

Absorption of energy in subjects was found to be well below the accepted levels, and no adverse events of any kind were identified. Participants also provided a positive response with no discomfort and minimal time spent in the device.

Further clinical prototype device advancement

Development of the Company’s clinical prototype device progressed well over the quarter, resulting in unique signalling systems. The imaging algorithms are now being modified to work effectively with these new hardware upgrades. At present, the Company intends to commence clinical trials in the second half of 2019.

ISO 13485 Certification Received from TÜV Rheinland

EMvision received ISO 13485 Certification from TÜV Rheinland during the quarter. This certifies that the Company has established and applies a quality management system for medical devices for the design and development of body imaging systems. ISO 13485 is also an essential requirement in obtaining European CE Mark and Australian Therapeutic Goods Administration (TGA) approval.

Initiated collection of liver samples to inform adjacent NAFLD / NASH Torso Scanner opportunity

In a collaboration with The University of Queensland and Metro South Hospital & Health Service, and via a \$160,000 Queensland Biomedical Assistance Fund grant, a research project is being undertaken to develop a potential novel, cost effective, portable and safe electromagnetic torso scanner. The system would utilise the same core technology being developed for brain imaging, with custom algorithms and hardware for the detection and monitoring of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). EMvision retains the rights to its intellectual property and intellectual property created during the research project.

During the quarter, the research team commenced the collection of patient liver samples at the Princess Alexandra Hospital with the aim to understand the baseline electrical properties of healthy and unhealthy liver tissue. The target date for the acquisition and analysis of this primary data is in the first half of 2019.

Due to the high prevalence of NAFLD and it's significant economic burden, there has been an urgent need to develop reliable, cost effective and non-invasive diagnostics that can accurately predict the presence of this life threatening disease without the need for liver biopsy.

Cashflow commentary and grant funding

Following completion of the initial public offer, the Company had cash reserves of \$5.844 million as at 31 December 2018. Net cash used in operating activities was \$0.622 million for the quarter and included costs associated with the listing of the Company's securities on the ASX, research and development of the clinical prototype and corporate administration.

The receipt of \$0.230 million in Cooperative Research Centre project (CRC-P) grant funding and participant contributions partially offset these costs.

EMvision was awarded a \$2.6 million CRC-P grant from the Government of the Commonwealth of Australia in late 2017, and, through the grant process, has established key academic, clinical and industry relationships that will assist in the advancement and commercialisation of the Company's brain scanner program. These partners have also committed to provide a further \$910,000 in grant funds to EMvision. To 31 December 2018, the Company has received \$984,990 from the government and \$137,500 from grant participant partners.

The grant participant partners include GE Healthcare, a US\$19 billion healthcare business of GE (NYSE:GE), The University of Queensland which is one of the world's top 10 universities for biotechnology, and The Queensland Government Metro South Hospital & Health Service operating at the Princess Alexandra Hospital, one of Australia's leading academic and research centres.

[ENDS]

For further information, media or investor enquires, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

ABOUT EMVISION

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

EMVISION MEDICAL DEVICES LTD

ABN

38 620 388 230

Quarter ended ("current quarter")

31 DECEMBER 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
- CRC-P participant contributions	46	91
1.2 Payments for		
(a) research and development	(223)	(615)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs including research and development staff	(294)	(382)
(f) administration and corporate costs	(294)	(435)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
- CRC-P grant income	184	584
1.8 Other (provide details if material)		
- Net GST received / (paid)	(41)	(40)
1.9 Net cash from / (used in) operating activities	(622)	(797)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) property, plant and equipment			
(b) businesses (see item 10)			
(c) investments			
(d) intellectual property			
(e) other non-current assets			
2.2 Proceeds from disposal of:			
(a) property, plant and equipment			
(b) businesses (see item 10)			
(c) investments			
(d) intellectual property			
(e) other non-current assets			
2.3 Cash flows from loans to other entities			
2.4 Dividends received (see note 3)			
2.5 Other (provide details if material)			
2.6 Net cash from / (used in) investing activities		0	0

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	6,000	6,000
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds/(refund) from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(369)	(369)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	5,631	5,631

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	835	1,010
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(622)	(797)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0
4.4	Net cash from / (used in) financing activities (item 3.10 above)	5,631	5,631
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of quarter	5,844	5,844

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,844	837
5.2	Call deposits		
5.3	Bank overdrafts	-	(2)
5.4	Other		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,844	835

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	118
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	0
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
-	Director fees, salaries and superannuation paid to Directors	

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	0
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	0
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	0	0
8.2 Credit standby arrangements	0	0
8.3 Other (please specify)	0	0
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(790)
9.2 Product manufacturing and operating costs	0
9.3 Advertising and marketing	0
9.4 Leased assets	0
9.5 Staff costs	(340)
9.6 Administration and corporate costs	(220)
9.7 Other (provide details if material)	
- CRC-P grant income	184
- CRC-P participant contributions	46
- Net GST	(35)
9.8 Total estimated cash outflows	(1,155)

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Company secretary)

Date: ..30 January 2019.....

Print name:Emma Waldon.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.